Cargando…
Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy
In this study, we aimed to evaluate the prognostic impact of sarcopenia, five-item modified frailty index (mFI-5), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) in patients with oral cavity squamous cell carcinoma (OSCC) treated with adjuvant chemoradiotherapy (CRT) and thei...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464994/ https://www.ncbi.nlm.nih.gov/pubmed/34575713 http://dx.doi.org/10.3390/jpm11090936 |
_version_ | 1784572757601681408 |
---|---|
author | Huang, Chun-Hou Chen, Peir-Rorg Lue, Kun-Han Hsieh, Tsung-Cheng Chou, Yu-Fu |
author_facet | Huang, Chun-Hou Chen, Peir-Rorg Lue, Kun-Han Hsieh, Tsung-Cheng Chou, Yu-Fu |
author_sort | Huang, Chun-Hou |
collection | PubMed |
description | In this study, we aimed to evaluate the prognostic impact of sarcopenia, five-item modified frailty index (mFI-5), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) in patients with oral cavity squamous cell carcinoma (OSCC) treated with adjuvant chemoradiotherapy (CRT) and their survival outcomes. We retrospectively enrolled 175 patients with OSCC undergoing adjuvant CRT between 2011 and 2018, who were divided into groups with (n = 112) and without (n = 63) sarcopenia. Logistic regression analysis and Cox proportional hazards models were used to determine prognostic factors for CRT-related toxicity, three-year overall survival (OS), and disease-free survival (DFS). Sarcopenia and high PLR were independently associated with CRT-induced anemia (CIA); advanced tumor stage was related to poor three-year OS. CRT and survival did not differ by mFI-5 and NLR. Our results indicate that sarcopenia and high PLR are significant predictors of adjuvant CRT, increasing toxicity outcomes and indicating worse short-term OS. Accurately identifying sarcopenia and high PLR in patients with OSCC is critical to help better select candidates for adjuvant CRT to improve their outcomes. |
format | Online Article Text |
id | pubmed-8464994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84649942021-09-27 Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy Huang, Chun-Hou Chen, Peir-Rorg Lue, Kun-Han Hsieh, Tsung-Cheng Chou, Yu-Fu J Pers Med Article In this study, we aimed to evaluate the prognostic impact of sarcopenia, five-item modified frailty index (mFI-5), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) in patients with oral cavity squamous cell carcinoma (OSCC) treated with adjuvant chemoradiotherapy (CRT) and their survival outcomes. We retrospectively enrolled 175 patients with OSCC undergoing adjuvant CRT between 2011 and 2018, who were divided into groups with (n = 112) and without (n = 63) sarcopenia. Logistic regression analysis and Cox proportional hazards models were used to determine prognostic factors for CRT-related toxicity, three-year overall survival (OS), and disease-free survival (DFS). Sarcopenia and high PLR were independently associated with CRT-induced anemia (CIA); advanced tumor stage was related to poor three-year OS. CRT and survival did not differ by mFI-5 and NLR. Our results indicate that sarcopenia and high PLR are significant predictors of adjuvant CRT, increasing toxicity outcomes and indicating worse short-term OS. Accurately identifying sarcopenia and high PLR in patients with OSCC is critical to help better select candidates for adjuvant CRT to improve their outcomes. MDPI 2021-09-19 /pmc/articles/PMC8464994/ /pubmed/34575713 http://dx.doi.org/10.3390/jpm11090936 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huang, Chun-Hou Chen, Peir-Rorg Lue, Kun-Han Hsieh, Tsung-Cheng Chou, Yu-Fu Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy |
title | Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy |
title_full | Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy |
title_fullStr | Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy |
title_full_unstemmed | Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy |
title_short | Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy |
title_sort | evaluation of sarcopenia, frailty, and inflammation on adverse events and survival outcomes in patients with oral cavity squamous cell carcinoma under adjuvant chemoradiotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464994/ https://www.ncbi.nlm.nih.gov/pubmed/34575713 http://dx.doi.org/10.3390/jpm11090936 |
work_keys_str_mv | AT huangchunhou evaluationofsarcopeniafrailtyandinflammationonadverseeventsandsurvivaloutcomesinpatientswithoralcavitysquamouscellcarcinomaunderadjuvantchemoradiotherapy AT chenpeirrorg evaluationofsarcopeniafrailtyandinflammationonadverseeventsandsurvivaloutcomesinpatientswithoralcavitysquamouscellcarcinomaunderadjuvantchemoradiotherapy AT luekunhan evaluationofsarcopeniafrailtyandinflammationonadverseeventsandsurvivaloutcomesinpatientswithoralcavitysquamouscellcarcinomaunderadjuvantchemoradiotherapy AT hsiehtsungcheng evaluationofsarcopeniafrailtyandinflammationonadverseeventsandsurvivaloutcomesinpatientswithoralcavitysquamouscellcarcinomaunderadjuvantchemoradiotherapy AT chouyufu evaluationofsarcopeniafrailtyandinflammationonadverseeventsandsurvivaloutcomesinpatientswithoralcavitysquamouscellcarcinomaunderadjuvantchemoradiotherapy |